Treatment of premenopausal patients with advanced or recurrent breast cancer by chemical ablation.
- Author:
Qiang SUN
1
;
Han-yuan HUANG
;
Yi-dong ZHOU
;
Feng MAO
;
Yue-qing YANG
;
Ying XING
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Breast Neoplasms; blood; drug therapy; Estrogens; blood; Female; Gonadotropin-Releasing Hormone; antagonists & inhibitors; Humans; Leuprolide; therapeutic use; Luteinizing Hormone; blood; Middle Aged; Neoplasm Recurrence, Local; prevention & control; Premenopause
- From: Acta Academiae Medicinae Sinicae 2003;25(1):60-62
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the clinical efficacy and safety of luteinizing hormone releasing hormone (LH-RH) analog in premenopausal patients with advanced or recurrent breast cancer.
METHODSLH-RH analog (enantone 3.75 mg/2 ml) were administered to 28 premenopausal patients with advanced recurrent breast cancer and its efficacy and side effect were observed.
RESULTSThe response rate (complete response and partial response) was 42.9%, and after 8 weeks of treatment, the plasma estrogen in all patients decreased to the level of postmenopause. No major adverse events were observed.
CONCLUSIONSLH-RH analog is effective and safe for premenopausal breast cancer with low adverse reaction and its administration method is easy.
